



**衛生防護中心**  
Centre for Health Protection

**Cancer Expert Working Group on  
Cancer Prevention and Screening (CEWG)**

**Recommendations on Prevention and Screening for Breast Cancer  
For Health Professionals**

**Local epidemiology**

Breast cancer (BC) has been the most common cancer among women in Hong Kong since the early 1990's. In 2018, there were 4,618 newly registered female BC cases, accounting for 27.2% of all new cancer cases in females.<sup>1</sup> The median age at diagnosis was 57 years and the lifetime risk before age 75 was 1 in 14.<sup>1</sup> The age-standardised incidence rate (ASIR) of female BC was 65.5 per 100,000 female population.<sup>1</sup> Being the third leading cause of cancer deaths among women in 2019, BC caused 852 deaths, representing 13.7% of all female cancer deaths.<sup>2</sup> The age-standardised mortality rate (ASMR) of female BC was 10.2 per 100,000 female population.<sup>2</sup>

2. After adjusting for population ageing, the ASIR of female BC had an upward trend for the period between 1991 and 2018 while the ASMR between 1991 and 2019 did not change significantly. The ASIR and ASMR of female BC in Hong Kong remained low when compared with the rates reported by a number of developed economies in the West (e.g.



Australia, United Kingdom [UK]) and the neighbouring Singapore.<sup>3</sup>

## **Risk factors for female breast cancer**

3. A range of factors accounts for women's risk of BC, among which family history being a strong known one.<sup>4,5,6,7,8,9</sup> Generally, for women with a family history of BC, the risk of developing BC increases with increasing degree of relatedness to the affected relatives; increasing number of affected relatives; and decreasing age at which affected relatives diagnosed with BC. Having one first-degree relative with BC doubles a woman's risk while having an affected second-degree relative increases risk by 50%.<sup>4,8</sup>

4. Women with certain deleterious gene mutations are at high risk of BC. Germline mutations in *BRCA1/2* genes are associated with 40% to 90% lifetime risk of BC and are the most common cause of hereditary breast cancer.<sup>7,8,10,11,12</sup> It has been estimated that *BRCA1/2* mutations contribute to 5% to 10% of breast cancer cases in Western countries.<sup>7,8</sup> Local data on the prevalence of *BRCA* mutations in the general population are limited, but information from the Hong Kong Hereditary Breast Cancer Family Registry suggested that *BRCA* mutation could be found in 9.6% of subjects out of 2,549 clinically high-risk\* breast or ovarian cancer patients.<sup>13</sup>

5. Other established risk factors include increasing age, history of receiving radiation therapy at young age, history of BC or ovarian cancer, history of benign breast diseases, exposure to exogenous hormones, reproductive factors (e.g. early menarche or late menopause, nulliparity, late first live birth), obesity after menopause, alcohol consumption and physical inactivity.

<sup>4,7,8,9,14,15,16,17,18,19,20,21,22,23,24,25,26,27</sup>

---

\* based on young age at diagnosis, multiple members with breast/ovarian/prostate and BRCA-related cancers in the family

## Primary prevention

6. Certain BC risk factors are modifiable and related to personal lifestyle and behaviour. Women can lower their risk of getting BC by pursuing primary preventive measures below:<sup>7,25,26,27</sup>

- *Be physically active.* Women should do at least 150 minutes of moderate-intensity or equivalent aerobic physical activities per week (e.g. climbing stairs or brisk walking, etc).
- *Do not drink alcohol.* Alcohol is a Group I carcinogen as classified by International Agency for Research on Cancer (IARC) of the World Health Organization (WHO). There is strong evidence that alcohol can cause, inter alia, female BC. With respect to cancer risk, there is no safe level for drinking alcohol. For women, drinking 10 grams of alcohol per day (e.g. 250 ml of beer with 5% alcohol content, a small glass (~100 ml) of red or white wine with 12% alcohol content) increases the risk of premenopausal BC by 5% and postmenopausal BC by 9%.<sup>27</sup>
- *Maintain a healthy body weight and waist circumference.* Asian women should aim for a body mass index (BMI) between 18.5 and 22.9, and a waist circumference of less than 80 cm (~32 inch).
- *Have childbirth at an earlier age and breastfeed each child for a longer duration.*

## **Breast awareness and early diagnosis**

7. Symptoms of early-stage BC may not be easily noticed. Therefore, all women are advised to be breast aware (i.e. being familiar with the normal look and feel of the breasts) and should visit doctors promptly if suspicious symptoms develop, examples of which included the presence of breast or axillary lump, change in the size or shape of the breasts, change in skin texture of the breasts or nipple, nipple rash, discharge or retraction, new and persistent discomfort or pain in the breast or axilla, etc. Delay in seeking medical attention may lead to more advanced stage at presentation and poorer survival.<sup>7,28</sup>

## **Screening for general female population**

8. Breast cancer screening aims to detect BC in asymptomatic population before symptoms develop so as to achieve better treatment outcome and improve survival. Subject to nature and performance, screening tests have both benefits (e.g. improvement in the detection of early-stage cancer when it is still treatable, reduction in BC mortality) and harms (e.g. psychological distress due to false-positives, over-diagnosis and over-treatment) to screened populations. Over the years, breast self-examination (BSE), clinical breast examination (CBE) and mammography (MMG), alone or in combination, are most widely studied screening modalities for BC screening.

### ***(a) Breast self-examination (BSE)***

9. Breast self-examination is a regular, formally taught and ritual examination of a woman's breasts by oneself at a monthly interval. Meta-analysis<sup>29</sup> and large-scale randomised controlled trials (RCTs) in Shanghai<sup>30</sup>

and Russia<sup>31</sup> respectively showed no difference on the size or stage of BC and number of BC deaths for women who had been taught to use systematic approach for BSE screening compared with those who had not. Instead, BSE were found to result in greater harm due to increased number of benign lesions and biopsies performed. Due to lack of evidence on the benefits of BSE screening but potential harms associated with false-positives, international guidelines<sup>32,33,34,35</sup> no longer recommend women to perform regular BSE screening, but rather support all women being aware of changes in their breasts and discussing these changes with clinicians.

**(b) Clinical breast examination (CBE)**

10. Clinical breast examination is physical examination of the breasts and the underarm area by a trained healthcare professional. Three RCTs (one conducted in the Philippines<sup>36</sup> and two in India<sup>37,38</sup>) on the efficacy of CBE screening alone versus no screening showed that screening by CBE could detect smaller and earlier stage of tumours or cancers, but did not report the effects of CBE on BC mortality. Studies from the Cochrane,<sup>29</sup> the American Cancer Society (ACS),<sup>32,39</sup> and the U.S. Preventive Services Task Force (USPSTF)<sup>33,34</sup> found either no or insufficient evidence to assess the association between population-based screening using CBE and BC mortality while the IARC<sup>7,35</sup> concluded inadequate evidence that screening by CBE reduces BC mortality.

**(c) Mammography (MMG)**

**Benefits of mammography screening**

11. Currently, standard MMG (i.e. 2-dimensional (2D) MMG) is the most common modality of screening women for BC. Evidence from Western countries suggests that organised MMG screening programmes are effective in

the detection of early-stage tumours and reduction in BC deaths in their female populations, especially among women aged 50-69 years.<sup>7,35,39,40,41,42</sup>

12. The ACS systematic review found that MMG screening was associated with an approximately 20% reduction in BC mortality of average-risk women after 13 years of follow-up.<sup>39</sup> When comparing with women aged <50, screening women aged  $\geq 50$  was associated with slightly greater BC mortality reduction, mostly due to greater reduction in women aged 60-69.<sup>39</sup> The USPSTF's review on the effectiveness of BC screening in average-risk women at different age groups showed the reduction in BC mortality for women aged 39-49 (relative risk [RR] 0.92, 95% CI 0.75-1.02), aged 50-59 (RR 0.86, 95% CI 0.68-0.97), aged 60-69 (RR 0.67, 95% CI 0.54-0.83) and aged 70-74 (RR 0.80, 95% CI 0.51-1.28) over 10 years of follow-up.<sup>40</sup> The IARC also found that women aged 50-69 years who attended organised MMG screening had about 40% reduction in the risk of BC mortality.<sup>7,35</sup>

### **Harms of mammography screening**

13. Although evidence supporting the use of MMG as tool for BC screening is not lacking, it is not 100% accurate for cancer detection and may even lead to harms by exposing women to risks, such as false-positives, false-negatives, over-diagnosis (the diagnosis of breast cancer, in particular to ductal carcinoma in situ [DCIS], as a result of screening that would not have been diagnosed or never have caused harm in a patient's lifetime if screening had not taken place), over-treatment, and complications arising from subsequent invasive investigations or treatment, and psychological distress.<sup>7,35,39,42,43,44,46</sup>

#### *False-positives*

14. False-positive screening results lead to recalls for additional imaging and subsequent invasive procedures (biopsy) with benign outcome. It has been reported that the 10-year cumulative false-positive rates and biopsies

were higher with annual screening than biennial screening (61% vs. 42% and 7% vs. 5%, respectively), for women aged 40 to 49 years and those with dense breasts.<sup>34,43</sup> The IARC estimated that the cumulative risk of false-positive recall in organised screening programmes was about 20% for woman who had 10 screens between the ages of 50 and 70 years, where less than 5% of all false-positive screens reported an invasive procedure.<sup>7,35</sup>

### *Over-diagnosis and over-treatment*

15. Over-diagnosis occurs when MMG detects DCIS, the majority of which would not progress to invasive cancer if left untreated. As the natural course of DCIS remains uncertain, the condition may be treated radically as invasive disease (e.g. with lumpectomy and radiation therapy) upon diagnosis because of uncertain outcome. That says, these women will be treated unnecessarily, or in other term “over-treatment”. Estimation on over-diagnosis varied widely with different study designs. Generally, observational studies estimated higher over-diagnosis rates with a range of 0% to 54% while RCTs suggested it be between 11% and 22%.<sup>34,43,46</sup> Systematic reviews, such as the Cochrane review,<sup>44</sup> reported MMG screening led to 30% over-diagnosis and over-treatment whereas the UK Independent Breast Review<sup>42</sup> estimated 11% over-diagnosis rate.

### *Psychological distress*

16. Women may experience anxiety while waiting for results of MMG screening or further investigations. Studies on psychological impact of false-positives showed varied results. The USPSTF systematic review indicated that women who received clear communication of their negative MMG results had minimal anxiety, whereas those recalled for further testing had more anxiety, breast cancer-specific worry and distress.<sup>34,43</sup> There were also studies showing women having false-positive MMG results generally have short-term negative psychological consequences.<sup>7,35</sup>

### *Pain and discomfort*

17. Although many women reported pain during MMG (ranging from 1% to 77%), those experiencing pain declined future screening varied from 11% to 46%.<sup>43</sup>

### *Risk of radiation exposure*

18. Radiation-induced BC is also a concern for women who are subjected to MMG screening. The IARC reported that the estimated cumulative risk of BC death due to radiation from MMG screening is 1 to 10 per 100,000 women, depending on age and the frequency and duration of screening, and these estimates are smaller than the estimates of BC deaths prevented by MMG screening by a factor of at least 100.<sup>7,35</sup>

### **Screening interval of mammography screening**

19. There has not been any RCTs identified directly comparing annual to biennial MMG screening in women of any age.<sup>32,34</sup> One United States (US) modelling study estimated that biennial screening from age 50 to 74 years avoided a median of 7 BC deaths versus no screening; while annual screening from age 40 to 74 years avoided an additional 3 deaths, but yielded 1,988 more false-positive results and 11 more over-diagnoses per 1,000 women screened. Annual screening from age 50 to 74 years was inefficient as there were similar benefits, but more harms than other strategies.<sup>45</sup> This study concluded that biennial screening is consistently the most efficient strategy for average-risk populations, and decisions about starting ages and intervals will depend on population characteristics and the decision makers' weight given to the harms and benefits of screening.<sup>45</sup> For overseas guidelines, the USPSTF<sup>34</sup> recommends biennial MMG screening for women aged 50-74 years while WHO recommends in well-resourced settings women aged 50-69 years should undergo organised, population-based MMG screening every two years.<sup>46</sup>



**(d) Digital breast tomosynthesis (DBT)**

20. Digital breast tomosynthesis (also known as 3D MMG) is a technique that produces quasi three-dimensional images of X-ray acquired over a limited range of angles around the breast. Preliminary evidence suggests that although DBT seems to lower recall rates for false-positive results and detect more cancers (both invasive BC and DCIS) as compared with conventional 2D MMG, DBT increases breast biopsy rates, and exposes women to more radiation.<sup>7,34,35,47,48</sup> Yet, current data is uncertain whether all of the extra BC cases detected by DBT actually represent a benefit (that is, cancer that is clinically significant rather than over-diagnosis). More importantly, no studies examined the effect of DBT on important health outcomes for women, such as reduction in morbidity or mortality of BC and quality of life. Currently, overseas professional organisations, such as the USPSTF,<sup>34</sup> Canadian Task Force on Preventive Health Care<sup>41</sup> and IARC<sup>7,35</sup> opined that there is insufficient evidence to support using DBT as a screening tool to reduce BC mortality or achieve lower rate of internal cancers. Future research should be warranted.

**(e) Ultrasonography**

21. Ultrasonography, used as an adjunct to MMG in women with radiologically dense breasts, has the potential of depicting small breast cancers not visible on MMG.<sup>49,50</sup> However, studies consistently showed that adjunct ultrasonography increased false-positive recall or testing.<sup>7,34,35,49,51</sup> Systematic reviews conducted by the Cochrane,<sup>51</sup> IARC<sup>7,35</sup> and USPSTF<sup>34</sup> concluded that there is insufficient evidence that ultrasonography as an adjunct to MMG screening can decrease BC mortality while the Canadian Task Force on Preventive Health Care<sup>41</sup> recommends not using ultrasonography to screen for BC in women at average risk.

## **Overseas' screening practice and recommendations for women at average risk**

22. Overall, age-based population screening with MMG is a common practice among developed economies including US, Australia, Canada, UK, Germany, Italy, Norway, Finland, and Singapore. Screening age from 50 to 69 years are more commonly adopted in European countries whereas extension of screening age from 50 to 74 are practised in US, Canada and Australia.<sup>52</sup> Screening for BC every 2 years is recommended in most of the countries (e.g. US, Australia, Germany, Norway, Singapore, etc).<sup>52</sup>

## **Screening for women at moderate and high risk**

### ***(a) Risk assessment and stratification***

23. In Western populations, a number of validated risk assessment tools (e.g. Gail model<sup>53</sup>) are available for prediction of individual woman's risk of developing BC in a quantitative manner based on different combination of risk factors. Each risk assessment tool has its own limitations and so far there is insufficient comparative evidence to recommend one tool over another.<sup>54</sup> Different countries adopt different algorithms for assessing risk and also different criteria for stratifying risk.<sup>54,55,56</sup>

24. Due to lack of comprehensive local data to identify women at moderate and high risk of BC, the CEWG based on its review on international studies and overseas practices (e.g. US,<sup>54</sup> UK,<sup>55</sup> Australia<sup>56, 57</sup>), made recommendations and derived local definition of women at moderate risk and high risk in 2010 by adopting a set of qualitative risk stratification criteria, which include *BRCAl/2* deleterious mutation carrier status, characteristics of family history and personal risk factors. Generally, the criteria promulgated by the

CEWG are in line with that of the aforementioned Western economies.

**(b) Mammography for women at high risk**

25. Although there has been no RCT on MMG screening specifically in women at high risk, observational studies concluded that MMG screening for high-risk population could be effective despite differences in study populations, criteria for risk stratification, screening protocols, and measures of effectiveness.<sup>58,59,60,61</sup> Having said that, MMG generally has lower sensitivity in younger women and those with a genetic predisposition to BC due to increased mammographic density obscuring the radiological features of early BC in premenopausal women, and a higher likelihood of benign mammographic images for *BRCA*-related breast cancer.<sup>62</sup>

**(c) Magnetic resonance imaging (MRI) for women at high risk**

26. Magnetic resonance imaging has been recommended as an adjunct to routine MMG for surveillance of women at high risk for its superior sensitivity over MMG alone for the detection of BC among *BRCA1/2* mutation carriers.<sup>63,64</sup> Studies reported that screening with MRI in women at high risk has significantly favourable shifting of cancer stage at diagnosis from advanced to earlier and pre-invasive stage when compared with other screening modalities (such as CBE, MMG, and ultrasonography).<sup>65,66,67</sup> UK survival analysis among women with high-risk genetic mutations reported that 10-year survival was significantly higher in the MRI-screened carriers of *BRCA1/2* mutations compared with unscreened ones, however no significant survival difference was found between the MMG plus MRI and MMG-only groups.<sup>68</sup> The IARC concluded with sufficient evidence that MRI as adjunct to MMG increases the sensitivity and decreases the specificity of screening in women with high familial risk and *BRCA1/2* mutation.<sup>7,35</sup> The radiation risk and false-positive rate of different

screening strategies (such as intensive MMG screening, with a combination of MMG and MRI) should be considered when making individual screening decisions.<sup>69</sup>

27. In addition, the 2019 USPSTF guideline recommended that clinicians should assess high-risk women with an appropriate familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.<sup>54</sup> There is also adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions are moderate for women with high risk whereas the associated harms are small to moderate.<sup>54</sup>

### **Hong Kong Breast Cancer study (HKBCS)**

28. To bridge the knowledge gap for risk prediction of BC in the local female population, the Government commissioned The University of Hong Kong (HKU) to conduct a case-control study in October 2015, funded by the Health and Medical Research Fund administered under the Food and Health Bureau. The study collated and analysed local data (3,501 BC cases and 3,610 controls) with the aim of developing a locally-validated, evidence-driven quantitative risk prediction tool for BC screening of higher risk individuals.<sup>70</sup>

29. HKBCS's risk stratification model estimated that the average lifetime risk of invasive BC among Hong Kong Chinese women was 6.8%, whereas the average lifetime risk of BC mortality was 1.1%. The HKU research team has developed a personalised risk assessment tool to estimate the risk of developing BC in women depending on a list of risk factors including age, presence of family history of BC among first-degree relatives, history of benign breast disease, age at menarche, age at first live birth, BMI and physical activity level.<sup>70</sup>

30. The HKBCS concluded that while the relative reduction in BC mortality among screenees provided by risk-based and conventional age-based BC screening were similar, the risk-based screening approach would be more cost-effective than the conventional age-based approach with reduction of unnecessary MMG and tissue biopsy due to false-positives among healthy women at low risk.<sup>70</sup> In other words, personalised risk-based biennial MMG screening for BC in women aged 44-69 could be more cost-efficient than universal age-based screening for Chinese women in Hong Kong. Having said that, this conclusion does not apply to the high risk group (e.g. *BRCA1/2* mutation carriers) and moderate risk group as defined by the CEWG.

### **Revised recommendations by CEWG**

31. After taking into consideration the findings of the HKBCS and available evidence, the CEWG has formulated the revised recommendations on BC screening which were later endorsed by the Cancer Coordinating Committee at its 15<sup>th</sup> meeting on 19 June 2020. The CEWG's revised BC screening recommendations for local female population include -

- (i) **Breast self-examination** is not recommended as a screening tool for breast cancer for asymptomatic women. Women are recommended to be breast aware (be familiar with the normal look and feel of their breasts) and seek medical attention promptly if suspicious symptoms arise.
- (ii) There is insufficient evidence to recommend **clinical breast examination** or **ultrasonography** as a screening tool for breast cancer for asymptomatic women.

(iii) It is recommended that risk-based approach should be adopted for breast cancer screening.

(iv) While the BC screening recommendations for (a) **women at high risk** remain *status quo*, those for (b) **women at moderate risk** and (c) other **women at general population** are revised. Details of recommendations for women at different risk profiles are listed as follows:

**(a) For women at high risk**

**CEWG Recommendations on BC screening for high risk:**

**Local definition - with any one of the risk factors:**

1. Carriers of *BRCA1/2* deleterious mutations confirmed by genetic testing.
2. Family history of breast cancer /ovarian cancer, such as
  - any first-degree female relative is a confirmed carrier of *BRCA1/2* deleterious mutations;
  - any first- or second-degree female relative with both breast cancer and ovarian cancer;
  - any first-degree female relative with bilateral breast cancer;
  - any male relative with a history of breast cancer;
  - 2 first-degree female relatives with breast cancer AND one of them being diagnosed at age  $\leq 50$  years;
  - $\geq 2$  first- or second-degree female relatives with ovarian cancer;
  - $\geq 3$  first- or second-degree female relatives with breast cancer OR a combination of breast cancer and ovarian cancer
3. Personal risk factors
  - history of radiation therapy to chest for treatment between age 10 and 30 years, e.g. Hodgkin's disease
  - history of breast cancer, including ductal carcinoma in situ (DCIS); lobular carcinoma
  - history of atypical ductal hyperplasia or atypical lobular hyperplasia

**Recommendation on screening**

1. Should seek advice from doctors; and
  - have mammography screening every year;
  - begin screening at age 35 or 10 years prior to the age at diagnosis of the youngest affected relative (for those with family history),

**CEWG Recommendations on BC screening for high risk:**

whichever is earlier, but not earlier than age 30.

- for confirmed carriers of *BRCA1/2* deleterious mutations or women who had radiation therapy to chest for treatment between age 10 and 30 years (e.g. for Hodgkin's disease), consider additional annual screening by magnetic resonance imaging (MRI).

**Recommendation on genetic testing**

1. Women who have any first-degree female relative with confirmed *BRCA1/2* deleterious mutations should be offered genetic testing to confirm or refute their carrier status.
2. For women at high risk due to other types of family history who wish to clarify their genetic risk or that of their family, referral to a specialist cancer clinic for advice, counselling and management should be discussed and considered.
3. Genetic testing should be performed by specialised cancer centres with expertise in genetic counselling, which should be provided before genetic testing. Healthcare professionals should discuss with their clients in detail about the uncertainties and implications of the test results. Confirmed carriers of *BRCA1/2* deleterious mutations who wish to consider prophylactic surgery / chemoprevention should also be referred to a specialist cancer clinic for advice and counselling.

**(b) For women at moderate risk**

**CEWG Recommendations on BC screening for moderate risk:**

1. Women at moderate risk (i.e. family history of only one first-degree female relative with breast cancer diagnosed at  $\leq 50$  years of age; or two first-degree female relatives diagnosed with breast cancer after the age of 50 years) are recommended to have mammography every two years and should discuss with their doctors the potential benefits and harms of breast cancer screening before starting screening.
2. MRI is not recommended for breast cancer screening in women at moderate risk.

### (c) For other women at general population

#### CEWG Recommendations on BC screening for average risk:

1. Women aged 44-69 with certain combinations of personalised risk factors (including presence of history of breast cancer among first-degree relative, a prior diagnosis of benign breast disease, nulliparity and late age of first live birth, early age of menarche, high body mass index and physical inactivity) putting them at increased risk of breast cancer are recommended to consider mammography screening every two years. They should discuss with their doctors on the potential benefits and harms before undergoing mammography screening.
2. A risk assessment tool for local women (e.g. one developed by The University of Hong Kong) is recommended to be used for estimating the risk of developing breast cancer with regard to the personalised risk factors described above.
3. MRI is not recommended for breast cancer screening in women at general population.

### January 2021

The copyright of this paper belongs to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. Contents of the paper may be freely quoted for educational, training and non-commercial uses provided that acknowledgement be made to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. No part of this paper may be used, modified or reproduced for purposes other than those stated above without prior permission obtained from the Centre.



## References

- <sup>1</sup> Hong Kong Cancer Registry, Hospital Authority. Female Breast Cancer in 2018. Available at: [https://www3.ha.org.hk/cancereg/pdf/factsheet/2018/breast\\_2018.pdf](https://www3.ha.org.hk/cancereg/pdf/factsheet/2018/breast_2018.pdf) [Accessed December 2020].
- <sup>2</sup> Department of Health and Census and Statistics Department, Hong Kong SAR. Mortality statistics of female breast cancer in 2019.
- <sup>3</sup> International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2018. Available at: <https://gco.iarc.fr> [Accessed November 2020].
- <sup>4</sup> Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer*. 1997;71:800-9.
- <sup>5</sup> Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *Lancet*. 2001;358:1389-1399.
- <sup>6</sup> Kharazmi E, Chen T, Narod S, et al. Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. *Breast Cancer Res Treat*. 2014;144:185-92.
- <sup>7</sup> International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, Volume 15. *Breast Cancer Screening*. France: World Health Organization; 2016.
- <sup>8</sup> PDQ® Cancer Genetics Editorial Board. *PDQ Genetics of Breast and Gynecologic Cancers*. Bethesda, MD: National Cancer Institute. Updated 4 November 2020. Available at: <https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq> [Accessed November 2020].
- <sup>9</sup> Colditz GA, Kaphingst KA, Hankinson SE, et al. Family history and risk of breast cancer: Nurses' Health Study. *Breast Cancer Res Treat*. 2012;133(3):1097-1104.
- <sup>10</sup> Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *J Natl Cancer Inst*. 2006;98:1694-706.
- <sup>11</sup> Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. *Ann Oncol*. 2015;26(7):1291-1299.
- <sup>12</sup> Kwong A, Chen JW, Shin VY. A new paradigm of genetic testing for hereditary breast/ovarian cancer. *Hong Kong Med J*. 2016;22:171-7.
- <sup>13</sup> Hong Kong Hereditary Breast Cancer Registry. Our Statistics: Analysis of participants recruited into research study till September 2017. Available at: <https://www.asiabreastregistry.com/en/hereditary-cancers/our-statistics> [Accessed June 2020].
- <sup>14</sup> Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol*. 2012;13:1141-51.
- <sup>15</sup> Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*. 1996;347:1713-27.
- <sup>16</sup> Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet*. 1997;350:1047-59.
- <sup>17</sup> Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2006;15:1899-905.
- <sup>18</sup> Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. *N Engl J Med*. 2005;353:229-37.
- <sup>19</sup> Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA*. 2003;290:465-75.

- 
- 20 Singletary SE. Rating the risk factors for breast cancer. *Ann Surg.* 2003;237:474-82.
- 21 Brinton LA, Hoover R, Fraumeni JF, Jr. Reproductive factors in the aetiology of breast cancer. *Br J Cancer.* 1983;47:757- 62.
- 22 Robinson D, Holmberg L, Møller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. *Br J Cancer.* 2008;99:611-5.
- 23 Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. *Breast Cancer Res Treat.* 2013;137:869-882.
- 24 Cancer Australia. *Risk factors for breast cancer: A review of the evidence 2018.* Available at: <https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/risk-factors-breast-cancer-review-evidence-2018> [Accessed June 2020].
- 25 International Agency for Research on Cancer. *List of Classifications by cancer sites with sufficient or limited evidence in humans, IARC Monographs Volumes 1 to 128.* Last update on 27 November 2020. Available at: [https://monographs.iarc.fr/wp-content/uploads/2019/07/Classifications\\_by\\_cancer\\_site.pdf](https://monographs.iarc.fr/wp-content/uploads/2019/07/Classifications_by_cancer_site.pdf) [Accessed January 2021].
- 26 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. *Lancet.* 2002;360:187- 95.
- 27 World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report: *Diet, Nutrition, Physical Activity and Breast Cancer. 2017.* Available at: <https://www.wcrf.org/sites/default/files/Breast-Cancer-2017-Report.pdf> [Accessed June 2020].
- 28 Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet.* 1999;353(9159):1119-1126.
- 29 Kösters JP, Göttsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Review). *The Cochrane Library.* 2008, Issue 4.
- 30 Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. *J Natl Cancer Inst.* 2002;94 (19):1445-57.
- 31 Semiglazov VF, Manikhas AG and Moiseenko VM. Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer. *Vopr Onkol.* 2003;49 (4):434-41.
- 32 Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. *JAMA.* 2015;314:1599–614.
- 33 U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;151(10):716–26.
- 34 Siu AL. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2016;164:279–96.
- 35 Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast cancer screening—viewpoint of the IARC working group. *N Engl J Med.* 2015; 372:2353-2358.
- 36 Pisani P, Parkin DM, Ngelangel C, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. *Int J Cancer.* 2006;118(1):149-154.
- 37 Mittra I, Mishra GA, Singh S, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. *Int J Cancer.* 2010;126(4):976-984.
- 38 Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. *J Natl Cancer Inst.* 2011;103(19):1476-1480.
- 39 Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. *JAMA.* 2015;314:1615–34.
- 40 Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med.* 2016;162:244-255.

- 
- 41 Klarenbach S, Sims-Jones N, Lewin G, et al. Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer. *CMAJ*. 2018;190:E1441-51.
- 42 Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013;108(11):2205-2240.
- 43 Nelson HD, Pappas M, Cantor A, et al. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med*. 2016;164:256–67.
- 44 Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. *The Cochrane database of systematic reviews*. 2013;6:CD001877.
- 45 Mandelblatt JS, Stout NK, Schechter CB, et al. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. *Ann Intern Med*. 2016;164(4):215-25.
- 46 World Health Organization. *WHO position paper on mammography screening*. 2014. Available at: [https://apps.who.int/iris/bitstream/handle/10665/137339/9789241507936\\_eng.pdf;jsessionid=D2DD6C57F1C3720A905DDD98E28EA589?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/137339/9789241507936_eng.pdf;jsessionid=D2DD6C57F1C3720A905DDD98E28EA589?sequence=1) [Accessed June 2020].
- 47 Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. *Lancet Oncol*. 2013;14:583-589
- 48 Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. *JAMA*. 2014;311(24):2499-507.
- 49 Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA*. May 14 2008;299(18):2151-2163.
- 50 Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. *Lancet*. Jan 23 2016;387(10016):341-348.
- 51 Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. *Cochrane Database Syst Rev*. 2013(4):CD009632.
- 52 Ebell MH, Thai TN and Royalty KJ. Cancer screening recommendations: an international comparison of high income countries. *Public Health Reviews*. 2018;39:7.
- 53 Gail MH, Benichou J. Validation studies on a model for breast cancer risk. *J Natl Cancer Inst*. 1994;86(8):573-5.
- 54 US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019;20;322(7):652-665.
- 55 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE Clinical Guideline. Published on 25 June 2013. Last updated on 20 November 2019. Available at: <https://www.nice.org.uk/guidance/cg164/chapter/Recommendations> [Accessed June 2020].
- 56 Cancer Australia. Advice about familial aspects of breast cancer and epithelial ovarian cancer: A guide for health professionals. December 2010. Available at: <https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/advice-about-familial-aspects-breast-cancer-and-epithelial-ovarian-cancer> [Accessed June 2020]
- 57 Cancer Australia. MRI for high risk women. Available at: <https://canceraustralia.gov.au/clinical-best-practice/breast-cancer/screening-and-early-detection/mri-high-risk-women>. [Accessed June 2020].
- 58 Maurice A, Evans DG, Shenton A, et al. Screening younger women with a family history of breast cancer—does early detection improve outcome? *Eur J Cancer*. 2006;42:1385-90.

- 
- <sup>59</sup> Kerlikowske K, Carney PA, Geller B, et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. *Ann Intern Med.* 2000;133:855-63.
- <sup>60</sup> Gui GP, Kadayaprath G, Darhouse N, et al. Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. *Eur J Surg Oncol.* 2006;32:719-24.
- <sup>61</sup> Cortesi L, Turchetti D, Marchi I, et al. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. *BMC Cancer.* 2006;6:210.
- <sup>62</sup> Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. *Eur J Cancer.* 2007;43:1905-17.
- <sup>63</sup> Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med.* 2008;148:671-9.
- <sup>64</sup> Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with *BRCA* mutations. *Br J Cancer.* 2012;107:24-30.
- <sup>65</sup> Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. *J Clin Oncol.* 2010;28:1450-7.
- <sup>66</sup> Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. *Invest Radiol.* 2011;46:94-105.
- <sup>67</sup> Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a *BRCA1* or *BRCA2* mutation under surveillance with and without magnetic resonance imaging. *J Clin Oncol.* 2011;29:1664-9.
- <sup>68</sup> Evans DG, Kesavan N, Lim Y, et al. MRI breast screening in high-risk women: cancer detection and survival analysis. *Breast Cancer Res Treat.* 2014;145:663-72.
- <sup>69</sup> Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in *BRCA1* and *BRCA2* gene mutation carriers: a comparative effectiveness analysis. *Cancer.* 2012;118:2021-30.
- <sup>70</sup> Health and Medical Research Fund (HMRF). Commissioned Study to The University of Hong Kong. *Preventing breast cancer in Hong Kong Chinese women through personalised risk stratification and characterization: an epidemiologic modeling study and the development of a biorepository of cases and controls.* Final Report. Available at: <https://rfs1.fhb.gov.hk/app/fundedsearch/projectdetail.xhtml?id=1903> [Accessed January 2021].